These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 23364608

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.
    Ford J, Milnes J, El Haou S, Wettwer E, Loose S, Matschke K, Tyl B, Round P, Ravens U.
    Heart Rhythm; 2016 Feb; 13(2):555-64. PubMed ID: 26455450
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
    Lagrutta A, Wang J, Fermini B, Salata JJ.
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, Gibson JK, Fedida D, Knaut M, Ravens U.
    Cardiovasc Res; 2013 Apr 01; 98(1):145-54. PubMed ID: 23341576
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
    Liu H, Jin MW, Xiang JZ, Huang Y, Sun HY, Chiu SW, Lau CP, Li GR.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):61-8. PubMed ID: 17337266
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology.
    Devalla HD, Schwach V, Ford JW, Milnes JT, El-Haou S, Jackson C, Gkatzis K, Elliott DA, Chuva de Sousa Lopes SM, Mummery CL, Verkerk AO, Passier R.
    EMBO Mol Med; 2015 Apr 01; 7(4):394-410. PubMed ID: 25700171
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
    Baczko I, Liknes D, Yang W, Hamming KC, Searle G, Jaeger K, Husti Z, Juhasz V, Klausz G, Pap R, Saghy L, Varro A, Dolinsky V, Wang S, Rauniyar V, Hall D, Dyck JR, Light PE.
    Br J Pharmacol; 2014 Jan 01; 171(1):92-106. PubMed ID: 24102184
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
    Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ.
    Med Sci Monit; 2004 Jul 01; 10(7):BR221-8. PubMed ID: 15232496
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.
    Wang Z, Fermini B, Nattel S.
    J Pharmacol Exp Ther; 1995 Jan 01; 272(1):184-96. PubMed ID: 7815332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.